お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
市場調査レポート
商品コード
967427

心筋梗塞治療薬の世界市場:2020年~2027年

Global Myocardial Infarction Drugs Market - 2020-2027

出版日: | 発行: DataM Intelligence | ページ情報: 英文 | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.84円
心筋梗塞治療薬の世界市場:2020年~2027年
出版日: 2020年10月23日
発行: DataM Intelligence
ページ情報: 英文
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

心筋梗塞は、心臓の一部への血流減少によって心筋が損傷を受けるもので、血流の減少は心臓への酸素供給の遮断も引き起こします。主な原因は、冠状静脈の内壁またはその小さな枝の1つにプラークが形成されるアテローム性動脈硬化症であり、糖尿病や脂質異常症などの危険因子を持つ人に多く発生します。

市場拡大の原動力となるのは、心血管疾患、高血圧、糖尿病、肥満の発生率の増加、ライフスタイルの変化、喫煙者数の増加、肥満や高血圧などの危険因子を有する人の増加、運動不足などの要因です。

当レポートは、世界の心筋梗塞治療薬の市場を調査したもので、市場の力学、業界の分析、新型コロナウイルス感染症(COVID-19)の影響分析、製品タイプ別、流通チャネル別、地域別の分析、競合情勢、企業プロファイルなどの情報を提供しています。

目次

第1章 調査手法と範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

  • 製品タイプ別市場
  • 流通チャネル別市場
  • 地域別市場

第4章 市場の力学

  • 市場に影響を与える要因
    • 促進要因
    • 抑制要因
    • 市場機会
    • 影響分析

第5章 業界分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • 償還分析
  • アンメットニーズ

第6章 COVID-19の影響分析

  • 市場に対するCovid-19の影響の分析
    • パンデミック前の市場シナリオ
    • 現在の市場シナリオ
    • パンデミック後または将来の市場シナリオ
  • Covid-19パンデミック下での価格の動向
  • 需給状況
  • パンデミック時の市場に関連する各国政府のイニシアチブ
  • メーカー各社の戦略的イニシアチブ
  • 結論

第7章 市場分析:製品タイプ別

  • イントロダクション
  • 市場規模と前年比成長率の分析
  • 市場魅力度指数
    • 鎮痛剤*
    • 抗血小板剤
    • 糖タンパク質IIb / IIIa阻害剤
    • 抗血栓剤
    • ベータアドレナリン遮断薬
    • 血管拡張薬
    • アンジオテンシン変換酵素(ACE)阻害剤
    • アンジオテンシン受容体遮断薬
    • その他

第8章 市場分析:流通チャネル別

  • イントロダクション
  • 市場規模と前年比成長率の分析
  • 市場魅力度指数
    • 病院*
    • 病院の薬局
    • ドラッグストア
    • オンラインドラッグストア

第9章 市場分析:地域別

  • イントロダクション
  • 市場規模と前年比成長率の分析
  • 市場魅力度指数
  • 北米
  • 欧州
  • 南米
  • アジア太平洋
  • 中東・アフリカ

第10章 競合情勢

  • 競合シナリオ
  • 市場でのポジショニング/シェア分析
  • 合併と買収の分析

第11章 企業プロファイル

  • Cadila Pharmaceuticals *
  • Bayer HealthCare LLC
  • Daiichi Sankyo, Inc.
  • Eli Lilly and Company
  • Janssen Biotech, Inc.
  • Merck & Co. Inc.
  • Novartis International AG
  • Sanofi
  • Par Pharmaceutical Companies, Inc.,
  • Mylan N.V.

第12章 主な調査結果

第13章 DataM Intelligenceについて

目次

Market Overview

The global myocardial infarction Drugs market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).

Myocardial infarction, commonly known as heart attack, occurs due to reduced blood flow to a part of the heart, causing damage to the heart muscle. The medications, which are used to treat heart attacks are known as myocardial infarction drugs. The reduced blood flow further causes blockage in the supply of oxygen to the heart, which is due to atherosclerosis, a process in which the plaque is formed on the inside wall of the coronary vein or one of its minor branches. Myocardial infraction occurs to individuals with risk factors such as diabetes and dyslipidemia.

Market Dynamics

The global myocardial infarction drugs market growth is driven by the growth in incidences of cardiovascular diseases as well as hypertension, diabetes, and obesity.

Increasing incidence of coronary artery disease and changes in lifestyle

Increasing incidence of coronary artery disease and changes in lifestyle are the major factors expected to drive the growth of global myocardial infarction therapeutics market. Increasing number of smokers, increasing incidence of obesity and blood pressures, lack of exercise can be some other reasons likely to flourish the global myocardial infarction therapeutics market over the forecast period. WHO data show that the death rate due to cardiovascular diseases is more in smokers than that in non-smokers.

Moreover, according to the Heart Foundation, by the end of 2014, approximately 920,000 people in the U.S. will have a heart attack. Thus, this large base of heart patients is expected to drive the market growth of the market in the forecast period.

High incidence rate of obesity along with chronic diseases will drive market

High incidence rate of obesity along with chronic diseases such as diabetes, hypertension and chronic kidney diseases are also driving the market growth. They are also embarking upon partnerships with retail chain companies to improve sales. urthermore, unhealthy lifestyle practices, excessive alcohol consumption and use of drugs such as amphetamines and cocaine, among population are the important risk factors for myocardial infarction, alternatively, which would boosts the growth of myocardial infarction drugs market in the near future. expected technological breakthroughs will generate abundant opportunities for detecting targeted blockages, monitoring cellular response and for determining genetic predisposition, which might alternatively drive the growth of the market.

Stringent regulatory policies and high costs of clinical trials is likely to hinder the market growth

On the contrary, rise in overall healthcare expenditure, stringent regulatory policies and high costs of clinical trials are some of the market-restraining factors that will hamper the growth of myocardial infarction drugs market in the forecast period.

COVID-19 Impact Analysis

Contrary to the anticipated surge in myocardial infarction (MI) related to the novel coronavirus, there have been reports that the COVID-19 pandemic has significantly reduced the number of activations for ST-elevation myocardial infarction (STEMI) in a majority of cities with devastating spread of COVID-19 cases. Thus, the pandemic has incresed the sale of drugs and ultimately growth of the myocardial infarction drugs market in the forecast period.

Market Segment Analysis

By product type, the myocardial infarction drugs market is classified into analgesics, antiplatelet agents, glycoprotein IIb/IIIa inhibitors, antithrombotic agents, beta-adrenergic blockers, vasodilators, angiotensin-converting enzyme (ace) inhibitors, and others.

Analgesics segment is expected to grow at the fastest CAGR during the forecast period (2020-2027)

Analgesics are also known as pain killer which is used to treat various different types of pain such as wounds, surgeries and others. There are various opioids and non-opioids and combination drugs are there which are used in the pain management. These drugs are generally used for unbearable pain and pain management. Pain management is a major domain for chronic disorders such as cancer, cardiovascular and others. For instance, according to American Heart Association (AHA), every year around 17.3 Mn people die of heart diseases worldwide, with myocardial infarction being the leading cause of death. In 2012, British Heart Foundation reported 73,680 deaths in United Kingdom due to coronary heart disease. Mortality from acute myocardial infarction can be decreased if patient receives the emergency access to the treatment.

In addition, the increasing therapeutic benefits offered by analgesics, in addition to effective and fast relief from pain, have significantly driven the demand for analgesics over the years. The development of innovative drugs and rising awareness about these treatment options have also supported the analgesics segment.

Morphine sulfate : Morphine sulfate is an opioid agonist indicated for the relief of moderate to severe acute and chronic pain where use of an opioid analgesic is appropriate. Morphine sulfate occurs as white, feathery, silky crystals; cubical masses of crystal; or white crystalline powder. It is soluble in water and slightly soluble in alcohol, but is practically insoluble in chloroform or ether. In addition to analgesia, the widely diverse effects of morphine sulfate include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.

Antiplatelet agents segment will also have the positive growth in the forecast period. An antithrombotic agent is a drug that reduces the formation of blood clots. Antithrombotic could be used therapeutically for prevention (primary prevention, secondary prevention) or treatment of a dangerous blood clot. Antithrombotic is a drug that helps reduce thrombus formation. Different antithrombotic affect different blood clotting processes like antiplatelet drugs, anticoagulants, and thrombolytic drugs. Its main application is to treat the abnormal blood flow in the human body. The major causes of thrombosis are inactivity, blood vessel damage, medical and genetic conditions, pregnancy, obesity. With the growing population across the globe, the demand for such life savings drugs is bound to increase. An antiplatelet drug is a member of a class of pharmaceuticals that decrease platelet aggregation and inhibit thrombus formation. They are effective in the arterial circulation. They are widely used in primary and secondary prevention of thrombotic cerebrovascular or cardiovascular disease.

For instance, according to the data provided by the American Heart Association, there are about 800,000 individuals suffer from stroke every year in the U.S. among these three out of four-experience stroke the very first time. Of these, 87% are ischemic strokes. Moreover, based on the data provided by the Centers for Disease Control and Prevention, 735,000 people have a heart attack in Latin America and North America. Of these 525,000 people experience heart attack the very first time. Thus, the growing trend of these diseases has led to the growth of the antiplatelet drugs.

Aspirin : Aspirin, also called acetylsalicylic acid, derivative of salicylic acid that is a mild nonnarcotic analgesic (pain reliever) useful in the relief of headache and muscle and joint aches. Aspirin is effective in reducing fever, inflammation, and swelling and thus has been used for treatment of rheumatoid arthritis, rheumatic fever, and mild infection. In these instances, aspirin generally acts on the symptoms of disease and does not modify or shorten the duration of a disease. However, because of its ability to inhibit the production of blood platelet aggregates (which may cut off the blood supply to regions of the heart or brain), aspirin has also been used as an anticoagulant in the treatment of conditions such as unstable angina or following a minor stroke or heart attack.

Vorapaxar : Vorapaxar is used to lower the risk of stroke or serious heart problems in people who have had a heart attack or a blood vessel disorder affecting circulation in the arms and legs.

It is found on platelets and is activated by thrombin resulting in platelet aggregation and formation of a vascular clot. The aggregation of platelets also plays an important role in the growth of atheromatous plaques, which can lead to coronary, cerebral and peripheral arterial occlusions.

Market Geographical Analysis

North America region holds the largest market share global Myocardial Infarction Drugs market

North America region is dominating the global myocardial infarction drugs market accounted for the largest market share in 2019, due to high incidence and prevalence rate of cardiac diseases coupled with increasing base of obese population. According to the Centers for Disease Control and Prevention (CDC), approximately 600,000 people in the U.S. die of heart disease annually. The organization also claims that annually the U.S. spends around USD 108.9 billion on treatment and management of coronary heart diseases. Moreover, according to the Heart Foundation, by the end of 2014, approximately 920,000 people in the U.S. will have a heart attack. Thus, this large base of heart patients is expected to drive the market growth of myocardial infarction treatment in this region.

On the other hand, Asia-Pacific is expected to exhibit the fastest growth rate over the forecast period. Owing to the high incidence rate of heart diseases and high adoption rate for advanced therapeutics, these regions are expected to be the potential market in the near future.

Market Competitive Landscape

The Myocardial Infarction Drugs market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Bayer HealthCare LLC, Daiichi Sankyo, Inc., Eli Lilly and Company, Janssen Biotech, Inc., Merck & Co. Inc., Novartis International AG and Sanofi amongst, Cadila Pharmaceuticals others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the myocardial infarction drugs market globally.

Cadila Pharmaceuticals

Overview: Cadila Pharmaceuticals Ltd. is privately held pharmaceutical companies in India, headquartered at Ahmedabad, in the State of Gujarat. Over the last six decades, the company has been developing and manufacturing pharmaceutical products in India and selling and distributing these in over hundred other countries around the world. More than 300 scientists in its various Research and Development setups reinforce the competitiveness of research in the therapeutic areas which have high unmet medical needs. Cadila Pharmaceuticals Excellence in manufacturing facilities is central to Cadila Pharmaceuticals. The company's formulations manufacturing plant at Dholka near Ahmedabad, Gujarat is spread over hundred acres of land. This state-of-the- art facility is not only impressive in size, but is also USFDA approved.

Product Portfolio: The Company's portfolio comprised of cardiovascular, gastrointestinal, analgesics, hematinic, anti-invectives' and antibiotics, respiratory agents, antidiabetics and immunological.

Key Development: In October 2020, Cadila Pharmaceuticals launches Tikacad in India, an anti-platelet drug-containing Ticagrelor, a P2Y12 platelet inhibitor indicated to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).

Why Purchase the Report?

  • Visualize the composition of the myocardial infarction drugs market segmentation by product type, and distribution channel highlighting the key commercial assets and players.
  • Identify commercial opportunities in myocardial infarction drugs market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of myocardial infarction drugs market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global myocardial infarction drugs market report would provide an access to an approx. 52 market data table, 48 figures and 250 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Myocardial Infarction Drugs Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Myocardial Infarction Drugs Market - Market Definition and Overview

3. Global Myocardial Infarction Drugs Market - Executive Summary

  • 3.1. Market Snippet by Product Type
  • 3.2. Market Snippet by Distribution Channel
  • 3.3. Market Snippet by Region

4. Global Myocardial Infarction Drugs Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing incidence of coronary artery disease and changes in lifestyle
      • 4.1.1.2. High incidence rate of obesity along with chronic diseases will drive market
    • 4.1.2. Restraints
      • 4.1.2.1. Stringent Regulatory Policies
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Myocardial Infarction Drugs Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Myocardial Infarction Drugs Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Myocardial Infarction Drugs Market - By Product Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
  • 7.3. Market Attractiveness Index, By Product Type Segment
    • 7.3.1. Analgesic*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
      • 7.3.1.3. Morphine sulfate
    • 7.3.2. Antiplatelet agents
      • 7.3.2.1. Aspirin
      • 7.3.2.2. Vorapaxar
      • 7.3.2.3. Clopidogrel
    • 7.3.3. Glycoprotein IIb/IIIa inhibitors
      • 7.3.3.1. Abciximab
      • 7.3.3.2. Tirofiban
      • 7.3.3.3. Eptifibatide
    • 7.3.4. Antithrombotic agents
      • 7.3.4.1. Heparin
      • 7.3.4.2. Bivalirudin
      • 7.3.4.3. Enoxaparin
    • 7.3.5. Beta-adrenergic blockers
      • 7.3.5.1. Metoprolol
      • 7.3.5.2. Esmolol
    • 7.3.6. Vasodilators
      • 7.3.6.1. Nitroglycerin
    • 7.3.7. Angiotensin-Converting Enzyme (ACE) inhibitors
      • 7.3.7.1. Enalapril
      • 7.3.7.2. Captopril
      • 7.3.7.3. Lisinopril
    • 7.3.8. Angiotensin-Receptor blockers
      • 7.3.8.1. Candesartan
      • 7.3.8.2. Valsartan
    • 7.3.9. Others

8. Global Myocardial Infarction Drugs Market - By Distribution Channel

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
  • 8.3. Market Attractiveness Index, By Distribution Channel Segment
    • 8.3.1. Hospitals *
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Hospital Pharmacies
    • 8.3.3. Drug Stores
    • 8.3.4. Online Drug Stores

9. Global Myocardial Infarction Drugs Market - By Region

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 9.3. Market Attractiveness Index, By Region
  • 9.4. North America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. U.S.
      • 9.4.5.2. Canada
      • 9.4.5.3. Mexico
  • 9.5. Europe
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. Germany
      • 9.5.5.2. U.K.
      • 9.5.5.3. France
      • 9.5.5.4. Italy
      • 9.5.5.5. Spain
      • 9.5.5.6. Rest of Europe
  • 9.6. South America
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.6.5.1. Brazil
      • 9.6.5.2. Argentina
      • 9.6.5.3. Rest of South America
  • 9.7. Asia Pacific
    • 9.7.1. Introduction
    • 9.7.2. Key Region-Specific Dynamics
    • 9.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.7.5.1. China
      • 9.7.5.2. India
      • 9.7.5.3. Japan
      • 9.7.5.4. Australia
      • 9.7.5.5. Rest of Asia Pacific
  • 9.8. Middle East and Africa
    • 9.8.1. Introduction
    • 9.8.2. Key Region-Specific Dynamics
    • 9.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Global Myocardial Infarction Drugs Market - Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Global Myocardial Infarction Drugs Market- Company Profiles

  • 11.1. Cadila Pharmaceuticals *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Bayer HealthCare LLC
  • 11.3. Daiichi Sankyo, Inc.
  • 11.4. Eli Lilly and Company
  • 11.5. Janssen Biotech, Inc.
  • 11.6. Merck & Co. Inc.
  • 11.7. Novartis International AG
  • 11.8. Sanofi
  • 11.9. Par Pharmaceutical Companies, Inc.,
  • 11.10. Mylan N.V.

LIST NOT EXHAUSTIVE

12. Global Myocardial Infarction Drugs Market - Premium Insights

13. Global Myocardial Infarction Drugs Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.